Facebook to crack down on ads that discourage vaccines

The social media giant, however, stopped short of banning anti-vax content.

The post added that while they already don’t allow ads featuring vaccine hoaxes, “Now, if an ad explicitly discourages someone from getting a vaccine, we’ll reject it.”

Moreover, the social media giant announced the launch of a new campaign to provide information about flu vaccines to users, and pledged to work with “global health partners on campaigns to increase immunization rates,” Jin and Leathern said.

PHOTO: The Facebook logo is displayed on a mobile phone in this picture illustration taken Dec. 2, 2019.

The Facebook logo is displayed on a mobile phone in this picture illustration taken Dec. 2, 2019.

Facebook’s policy, however, stops short of banning posts or other types of content on the platform that discourages vaccines. It also does not ban political ads that “advocate for or against legislation or government policies around vaccines — including a COVID-19 vaccine,” Jin and Leathern wrote.

“We’ll continue to require anyone running these ads to get authorized and include a ‘Paid for by’ label so people can see who is behind them,” the blog post stated.

Source Article

Read More →

South Africa’s Biovac in talks to manufacture COVID-19 vaccines

By Wendell Roelf and Alexander Winning

CAPE TOWN (Reuters) – A South African company part-owned by the government is in talks with the global COVID-19 vaccine distribution scheme and pharmaceutical companies to produce some of the vaccines the country needs to protect itself against the disease.

The Biovac Institute, a Cape Town-based joint venture between the government and private sector, could produce up to 30 million doses of COVID-19 vaccines per year, depending on the technology involved, Chief Executive Morena Makhoana told Reuters.

Depending on whether the vaccines require a one- or two-dose regimen, that could be enough for a quarter or half of South Africa’s population.

“We need to look at who is likely to get to the finishing line and who has the technological fit,” Makhoana said, when asked which vaccine candidate Biovac might partner with. “Discussions are happening and we are fairly confident that … we will be able to clinch a deal.”

The Coalition for Epidemic Preparedness Innovations (CEPI), the foundation that co-leads the COVAX scheme alongside the World Health Organization and vaccines alliance GAVI, has identified Biovac as a potential drug product manufacturer but has not signed an agreement yet, a CEPI spokesman said.

Drug product manufacturing typically includes steps like vaccine formulation, filling and finishing of vials, labelling and packaging, he said.

The COVAX scheme aims to deliver 2 billion doses of COVID-19 vaccine by the end of 2021. CEPI is reserving capacity with vaccine manufacturers worldwide so that goal can be met.

South Africa has submitted a non-binding confirmation of intent to participate in COVAX.

Makhoana said Biovac could not make “live virus” vaccines at this stage, precluding some vaccines being trailed in South Africa in partnership with Oxford University and Johnson & Johnson. He declined to name the companies Biovac was speaking to.

The Department of Science and Innovation, the ministry that manages the government’s stake in Biovac, supports its ambitions because it wants to stimulate local manufacturing and limit the impact of vaccine procurement on the country’s balance of payments, Director-General Phil Mjwara said.

Currently South Africa’s government buys about 95% of the vaccines supplied annually by Biovac, covering diseases such as tuberculosis, cervical cancer and influenza, with the rest sold to countries in the rest of Africa.

In the past Biovac has partnered with companies like Pfizer and Sanofi.

(Reporting by Wendell Roelf and Alexander Winning; Editing by Tim Cocks and Elaine Hardcastle)

Source Article

Read More →

World Bank approves $12B to finance virus vaccines, care

The World Bank has approved $12 billion in financing to help developing countries buy and distribute coronavirus vaccines, tests, and treatments, aiming to support the vaccination of up to 1 billion people.

The $12 billion “envelope” is part of a wider World Bank Group package of up to $160 billion to help developing countries fight the COVID-19 pandemic, the bank said in a statement late Tuesday.

The World Bank said its COVID-19 emergency response programs are already reaching 111 countries.

Citizens in developing countries also need access to safe and effective COVID-19 vaccines, it said.


“We are extending and expanding our fast-track approach to address the COVID emergency so that developing countries have fair and equal access to vaccines,” said the bank’s president, David Malpass, said in the statement.

“Access to safe and effective vaccines and strengthened delivery systems is key to alter the course of the pandemic and help countries experiencing catastrophic economic and fiscal impacts move toward a resilient recovery,” he said.

The International Finance Corporation, the private sector lending arm of the World Bank is investing in vaccine manufacturers through a $4 billion Global Health Platform, the World Bank said.

Researchers are working on developing more than 170 potential COVID-19 vaccines.

Development and deployment of such preventive vaccines is crucial to helping stem outbreaks of the coronavirus that has killed more than 1 million people and sickened more than 38 million, while devastating economies and leaving many millions jobless.

The world’s richest countries have locked up most of the world’s potential vaccine supply through 2021, raising worries that poor and vulnerable communities will not be able to get the shots. Meanwhile, an ambitious international project to deliver coronavirus vaccines to the world’s poorest people, called Covax, is facing potential shortages of money, cargo planes, refrigeration and vaccines themselves.

The World Bank said it will draw on expertise and experience from its involvement in many large-scale immunization programs and other public health efforts.

The funding also is meant to help countries access tests and treatments and to support management of supply chains and other logistics for vaccinations in developing countries, the bank said.

Source Article

Read More →

World Bank Approves $12B to Finance Virus Vaccines, Care | Business News

The World Bank has approved $12 billion in financing to help developing countries buy and distribute coronavirus vaccines, tests, and treatments, aiming to support the vaccination of up to 1 billion people.

The $12 billion “envelop” is part of a wider World Bank Group package of up to $160 billion to help developing countries fight the COVID-19 pandemic, the bank said in a statement late Tuesday.

The World Bank said its COVID-19 emergency response programs are already reaching 111 countries.

Citizens in developing countries also need access to safe and effective COVID-19 vaccines, it said.

“We are extending and expanding our fast-track approach to address the COVID emergency so that developing countries have fair and equal access to vaccines,” said the bank’s president, David Malpass, said in the statement.

“Access to safe and effective vaccines and strengthened delivery systems is key to alter the course of the pandemic and help countries experiencing catastrophic economic and fiscal impacts move toward a resilient recovery,” he said.

The International Finance Corporation, the private sector lending arm of the World Bank is investing in vaccine manufacturers through a $4 billion Global Health Platform, the statement said.

Development and deployment of vaccines is crucial to helping stem outbreaks of the coronavirus that has killed more than 1 million people and sickened more than 38 million, while devastating economies and leaving many millions jobless.

The World Bank said it will draw on expertise and experience from its involvement in many large-scale immunization programs and other public health efforts.

The funding is meant to also help countries access tests and treatments and to support management of supply chains and other logistics for vaccinations in developing countries, the bank said.

Copyright 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Source Article

Read More →

World Bank approves $12 bln for Covid-19 vaccines

The World Bank said Tuesday that it approved $12 billion for developing countries to finance the purchase and distribution of Covid-19 vaccines, tests and treatment.

The financing “aims to support vaccination of up to a billion people,” the bank said in a statement.

The money is part of an overall World Bank Group (WBG) package of up to $160 billion through June 2021 designed to help developing countries battle the novel coronavirus pandemic.

“This financing package helps signal to the research and pharmaceutical industry that citizens in developing countries also need access to safe and effective Covid-19 vaccines,” the statement read. 

“It will also provide financing and technical support so that developing countries can prepare for deploying vaccines at scale, in coordination with international partners.”

Access to safe and effective vaccines “and strengthened delivery systems is key to alter the course of the pandemic and help countries experiencing catastrophic economic and fiscal impacts move toward a resilient recovery,” World Bank Group President David Malpass said in the statement.

The financing “will also support countries to access to Covid-19 tests and treatments, and expand immunization capacity to help health systems deploy the vaccines effectively,” the statement added.

The financing approval was expected as Malpass had announced the project in late September.

While vaccines have yet to appear on the market, Malpass noted in an interview with the French daily Le Figaro that it was necessary to prepare because of the complicated vaccine distribution process.

The Bank’s approach, according to the statement, draws on its “significant expertise in supporting large scale immunization programs for vaccine preventable diseases, as well as public health programs to tackle infectious diseases such as HIV, tuberculosis, malaria and neglected tropical diseases.”

dt/ch/dw

Source Article

Read More →